Vivo Capital LLC purchased a new stake in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) in the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 6,818,181 shares of the company’s stock, valued at approximately $7,432,000.
Other institutional investors have also recently bought and sold shares of the company. Private Advisor Group LLC boosted its stake in Matinas BioPharma by 100.4% during the 4th quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after purchasing an additional 24,978 shares during the period. BlackRock Inc. lifted its stake in shares of Matinas BioPharma by 147.1% in the 4th quarter. BlackRock Inc. now owns 290,589 shares of the company’s stock worth $173,000 after acquiring an additional 173,005 shares during the period. IPG Investment Advisors LLC lifted its stake in shares of Matinas BioPharma by 54.5% in the 1st quarter. IPG Investment Advisors LLC now owns 42,500 shares of the company’s stock worth $46,000 after acquiring an additional 15,000 shares during the period. Tibra Equities Europe Ltd acquired a new stake in shares of Matinas BioPharma in the 1st quarter worth approximately $264,000. Finally, Virtu Financial LLC lifted its stake in shares of Matinas BioPharma by 80.0% in the 1st quarter. Virtu Financial LLC now owns 116,636 shares of the company’s stock worth $127,000 after acquiring an additional 51,853 shares during the period.
In other news, Director Adam K. Stern purchased 80,000 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were acquired at an average price of $0.94 per share, for a total transaction of $75,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders purchased a total of 140,000 shares of company stock worth $129,300 over the last quarter.
Matinas BioPharma (NYSEAMERICAN:MTNB) last released its earnings results on Monday, May 13th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01).
A number of analysts have recently weighed in on MTNB shares. BTIG Research started coverage on shares of Matinas BioPharma in a research note on Friday, May 17th. They issued a “buy” rating and a $5.00 price target for the company. Maxim Group reaffirmed a “buy” rating and issued a $5.00 price target on shares of Matinas BioPharma in a research note on Thursday, May 16th. Finally, Zacks Investment Research upgraded shares of Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Tuesday, April 16th.
COPYRIGHT VIOLATION NOTICE: “Vivo Capital LLC Takes $7.43 Million Position in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB)” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2019/06/12/vivo-capital-llc-takes-7-43-million-position-in-matinas-biopharma-holdings-inc-nyseamericanmtnb.html.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Further Reading: Understanding Average Daily Trade Volume
Want to see what other hedge funds are holding MTNB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB).
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.